CSBio CSBio

X
[{"orgOrder":0,"company":"SpliceBio","sponsor":"Ysios Capital","pharmaFlowCategory":"D","amount":"$56.6 million","upfrontCash":"Undisclosed","newsHeadline":"SpliceBio Raises EUR 50M in Oversubscribed Series A Financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"SPAIN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"SpliceBio"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The proceeds from the financing, the largest Series A round for a Spanish biotech company, will enable SpliceBio to build a pipeline of Protein Splicing gene therapy programs, while advancing the lead program in Stargardt disease to the clinic.

            Lead Product(s): AAV-based Gene Therapy

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Ysios Capital

            Deal Size: $56.6 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing February 16, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY